88 related articles for article (PubMed ID: 18650247)
1. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
[TBL] [Abstract][Full Text] [Related]
2. Selective metabolism of vincristine in vitro by CYP3A5.
Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.
Dai Y; Hebert MF; Isoherranen N; Davis CL; Marsh C; Shen DD; Thummel KE
Drug Metab Dispos; 2006 May; 34(5):836-47. PubMed ID: 16501005
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.
Brown HS; Griffin M; Houston JB
Drug Metab Dispos; 2007 Feb; 35(2):293-301. PubMed ID: 17132764
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications.
Henshall J; Galetin A; Harrison A; Houston JB
Drug Metab Dispos; 2008 Jul; 36(7):1332-40. PubMed ID: 18420779
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.
Zhao P; Kunze KL; Lee CA
Drug Metab Dispos; 2005 Jun; 33(6):853-61. PubMed ID: 15743977
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.
McGinnity DF; Soars MG; Urbanowicz RA; Riley RJ
Drug Metab Dispos; 2004 Nov; 32(11):1247-53. PubMed ID: 15286053
[TBL] [Abstract][Full Text] [Related]
10. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
11. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
Zhao P; Lee CA; Kunze KL
Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
[TBL] [Abstract][Full Text] [Related]
12. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
13. Species difference of metabolic clearance of bisphenol A using cryopreserved hepatocytes from rats, monkeys and humans.
Kurebayashi H; Okudaira K; Ohno Y
Toxicol Lett; 2010 Oct; 198(2):210-5. PubMed ID: 20599483
[TBL] [Abstract][Full Text] [Related]
14. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
15. Phase I and II metabolism and carbohydrate metabolism in cultured cryopreserved porcine hepatocytes.
Loven AD; Olsen AK; Friis C; Andersen B
Chem Biol Interact; 2005 Jun; 155(1-2):21-30. PubMed ID: 15950209
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes.
Lu C; Li P; Gallegos R; Uttamsingh V; Xia CQ; Miwa GT; Balani SK; Gan LS
Drug Metab Dispos; 2006 Sep; 34(9):1600-5. PubMed ID: 16790553
[TBL] [Abstract][Full Text] [Related]
19. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
20. Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1.
Li AP
Chem Biol Interact; 2009 Apr; 179(1):4-8. PubMed ID: 18950609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
